ClinicalTrials.gg
RecruitingNCT07943702Updated Nov 17, 2026

Correlation Between Visual Reading and DOlab Software Quantitative Analysis of DaT-SPECT Images

An observational study in Parkinsonian Disorders, Parkinson Disease and Lewy Body Disease, sponsored by Dorian Technologies S.r.l.. Recruiting at 2 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Dorian Technologies S.r.l. · Observational

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
120
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Parkinsonian Disorders with a site in Italy — 5 open to participants now, 5 under way, none of them phase 3. Parkinsonian Disorders · Italy.

Started
2026
with 1 other
Observational
6 of 23
5 open now
Registered
23rd of 23
by date
Lead sponsor
1 of 23
Dorian Technologies S.r.l.

Among the 23 studies in Parkinsonian Disorders with a site in Italy, this one is one of 2 that started in 2026, is one of 6 observational ones, and was the 23rd registered.

Parkinsonian Disorders

218 studies on the registry are indexed under Parkinsonian Disorders; 63 are open to participants now.

Browse Parkinsonian Disorders studies →

Open to participants now

5 of the 23 studies in Parkinsonian Disorders with a site in Italy are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 45 Parkinsonian Disorders studies recruiting now, 18 (40%) set no upper age limit and 9 (20%) stop at 75 or younger; 4 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Parkinsonian Disorders with a site in Italy, or all of them as a file.
02

Study summary

The goal of this study is to find out whether the quantitative results of DOlab software (DaT-SPECT workflow) agree with the visual reading of brain scans performed by nuclear medicine physicians. The scans are 123I-ioflupane DaT-SPECT images of adults who were evaluated for dopamine transporter dysfunction, a condition seen in Parkinson's disease, other parkinsonian syndromes and dementia with Lewy bodies.

The main questions it aims to answer are:

  • Do the visual scores given by expert readers (0 = normal to 3 = marked abnormality) correlate with the values calculated by the software?
  • Does using the software report change or refine the readers' classification compared with visual reading alone?
  • How usable do readers find the software?

The study uses existing scans of 120 patients collected between January 2015 and May 2025 at two Italian hospitals. No new tests or treatments are given to participants, and the software results are not used for their clinical care.

Read the detailed description

Dopamine transporter (DaT) SPECT with 123I-ioflupane is widely used to support the diagnosis of neurological disorders associated with nigrostriatal dopaminergic degeneration. Visual reading by trained physicians is the clinical standard, and semi-quantitative analysis is recommended by the EANM/SNMMI guidelines as an objective complement, especially in borderline cases.

DOlab software - DaT-SPECT workflow (Dorian Technologies; investigational, not CE-marked, class IIa) iteratively maps each scan to MNI space with adaptive volumes of interest for the right and left caudate, anterior putamen and posterior putamen, plus an occipital reference region. It computes four metrics: striatal binding ratio (SBR), Southampton SBR, Basal Ganglia V3 and Volume Fraction. The results are compared with a normative database derived from the Parkinson's Progression Markers Initiative (PPMI) and reported as z-scores.

This is a blinded, multicenter, retrospective investigation at two Italian sites. At each site, an independent reader selects 15 consecutive scans for each visual grade (0, 1, 2, 3), for a total of 120 scans. The images are pseudonymized and uploaded to a shared repository.

Phase 1: four independent readers (two per site), blinded to all clinical information except sex and age, visually score the randomized images (0-3) for the caudate, anterior putamen and posterior putamen of each hemisphere. In parallel, the software analyzes the same images, and the visual scores are correlated with the software metrics.

Phase 2: the images are re-randomized and re-coded, and the same readers perform a semi-quantitative assessment supported by the software report. Classifications from the two phases are then compared. Finally, the readers complete the System Usability Scale (SUS).

Sample size: 85 subjects are needed to detect a correlation of 0.30 (two-sided alpha 0.05, power 80%). 120 subjects are planned to allow for non-evaluable images.

03

Conditions studied

  • Parkinsonian Disorders
  • Parkinson Disease
  • Lewy Body Disease
  • Movement Disorders

Keywords

  • dopamine transporter
  • DaT-SPECT
  • 123I-ioflupane
  • DaTscan
  • nigrostriatal degeneration
  • semi-quantitative analysis
  • striatal binding ratio
  • software as a medical device
  • image analysis
  • visual interpretation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults referred for evaluation of nigrostriatal dopaminergic dysfunction who underwent 123I-ioflupane DaT-SPECT between January 2015 and May 2025 at Santo Stefano Hospital (Prato) or the University Hospital of Padua, Italy. At each center, 15 consecutive scans per visual grade (negative, mild, moderate and marked abnormality) are selected retrospectively.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • Referred for evaluation of nigrostriatal dopaminergic dysfunction to one of the participating centers between January 2015 and May 2025.
  • for data collection, or documentation that all reasonable efforts to obtain consent were made (Italian Privacy Code, art. 110).
  • 123I-ioflupane SPECT images that:
  • were acquired according to the PPMI imaging protocol;
  • have a field of view covering the entire head, from the superior cortical regions to the lower cerebellum;
  • followed the radiotracer manufacturer's acquisition timing and methods;
  • were attenuation-corrected according to local standard procedures.

Exclusion criteria

Exclusion Criteria:

  • Age under 18 years.
  • Use of drugs or substances that may significantly affect DaT binding (e.g., cocaine, amphetamines, CNS stimulants, opioid derivatives, antidepressants, adrenergic agonists, anticholinergics, anesthetics) without a of at least five biological half-lives before DaT-SPECT, per the EANM/SNMMI guidelines.
  • DaT-SPECT performed outside the January 2015 - May 2025 period.
  • Images not meeting the acquisition and quality specifications listed above.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
120 participants (estimated)
Patient registry
No

Groups and cohorts

  • Adults referred for DaT-SPECT

    Adults referred for evaluation of nigrostriatal dopaminergic dysfunction at the two participating centers between January 2015 and May 2025, whose existing 123I-ioflupane DaT-SPECT scans were selected retrospectively (30 per visual grade 0-3, 15 per grade per center). Each scan is read visually by four blinded readers, analyzed by DOlab software, and then re-read with the software report.

    Device: DOlab software - DaT-SPECT workflow · Diagnostic Test: Visual interpretation (comparator)

Interventions

  • DeviceDOlab software - DaT-SPECT workflow

    Investigational software (not CE-marked, class IIa) that automatically quantifies striatal 123I-ioflupane binding using four metrics (SBR, Southampton SBR, Basal Ganglia V3, Volume Fraction) and compares them with a PPMI-based normative database. It is applied retrospectively to existing images, and its output is not used for patient care.

  • Diagnostic testVisual interpretation (comparator)

    Visual reading of the same 123I-ioflupane images by blinded nuclear medicine physicians, scored 0-3 for the caudate, anterior putamen and posterior putamen of each hemisphere, according to the EANM/SNMMI guidelines.

06

What researchers measure

Primary outcomes

  1. Correlation between visual score and DOlab quantitative metrics

    Pearson correlation coefficient (with 95% CI) between the readers' visual score (ordinal 0-3; 0 = normal, 3 = marked abnormality) and each continuous metric produced by DOlab software (SBR, Southampton SBR, Basal Ganglia V3, Volume Fraction) for the caudate, anterior putamen and posterior putamen of each hemisphere. If the Pearson assumptions are not met, the Spearman rank correlation is reported.

    Time frame: Phase 1 reading session, within 4 months of study start

Secondary outcomes

  1. Agreement between visual and software-supported semi-quantitative classification

    Cohen's kappa coefficient between the classifications given by the same readers with visual reading alone (Phase 1) and with the DOlab software report (Phase 2).

    Time frame: Phase 2 reading session, within 4 months of study start

  2. Number of scans reclassified with software support

    Number and percentage of scans whose classification changes between visual reading alone and software-supported reading (e.g., borderline to abnormal), tested with McNemar's test for paired proportions.

    Time frame: Phase 2 reading session, within 4 months of study start

  3. Software usability (System Usability Scale)

    SUS questionnaire completed by the 4 readers: 10 items on a 5-point scale. SUS total score from 0 to 100, where higher scores indicate better perceived usability; item responses are also reported as median and IQR.

    Time frame: After the Phase 2 reading session, within 4 months of study start

07

Study locations

2 of 2 sites recruiting
  • Azienda USL Toscana Centro - Ospedale Santo Stefano
    Prato, Tuscany 59100, Italy
    Recruiting
    • Stelvio Sestini, MD · Principal investigator
  • Azienda Ospedale Università Padova
    Padova, Veneto 35128, Italy
    Recruiting
    • Diego Cecchin, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — Individual participant data and images will not be shared, because the clinical investigation plan restricts data use to the sponsor and investigators and the dataset includes pseudonymized imaging data of patients who could not all be reconsented. Aggregate results will be published.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2026 (actual). Primary completion is estimated for Jan 2027, 3 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartActual
Oct 13, 2026
Primary completionEst.
Jan 2027
CompletionEst.
Mar 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07943702
Lead sponsor
Dorian Technologies S.r.l.
Collaborators
JSB Solutions S.R.L.
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Oct 13, 2026
Primary completion
Jan 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Paolo Bosco
Contact
paolo.bosco@dorian-tech.com
+39 320 070 6224
Stelvio Sestini, MD
principal investigator · Azienda USL Toscana Centro - Santo Stefano Hospital, Prato

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion